Company Profiles

driven by the PitchBook Platform

Obsidian Therapeutics

Obsidian Therapeutics
2015 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Series A LATEST DEAL TYPE
$49.5M LATEST DEAL AMOUNT
8 INVESTORS
Description

Developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy to every patient with cancer. The company's next-generation cell and gene therapies with pharmacologic operating systems provide exquisite control of protein activity in cells and create adoptive cell therapies with new functions that are under control of the treating physician using simple, safe, orally-active, marketed drugs, enabling patients to improve on the current generation of cell therapies.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
1030 Massachusetts Avenue
Suite 400
Cambridge, MA 02138
United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Obsidian Therapeutics’s full profile, request a free trial.

Obsidian Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series A) 06-Dec-2017 $49.5M 000.00 000.00 Completed Generating Revenue
2. Accelerator/Incubator 15-Apr-2017 Completed Generating Revenue
1. Seed Round 01-Jan-2016 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Obsidian Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
dummy 00,000,000 00.00 00.00 00 00.00 00.000
Series A-2 00,000,000 00.000000 00 00 00 00 00.000
Series A-1 30,998,140 $0.000100 $1.13 $1.13 1x $1.13 45.89%
To view this company’s complete Cap Table, request access »

Obsidian Therapeutics Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Alexandria Venture Investments Corporate Venture Capital Minority 000 0000 000000 0
Amgen Ventures Corporate Venture Capital Minority 000 0000 000000 0
GV Corporate Venture Capital Minority 000 0000 000000 0
ShangPharma Innovation Venture Capital Minority 000 0000 000000 0
Takeda Ventures Corporate Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »

Obsidian Therapeutics Executive Team (6)

Name Title Board
Seat
Contact
Info
Michael Gilman Ph.D Chief Executive Officer & Board Member
Vipin Suri Ph.D Vice President, Head of Discovery & Co-Founder
Thomas Wandless Scientific Co-Founder
Tariq Kassum MD Co-Founder, Senior Vice President and Head of Business Operations
Steve Shamah Ph.D Senior Vice President & Head of Research
You’re viewing 5 of 6 executives. Get the full list »

Obsidian Therapeutics Board Members (8)

Name Representing Role Since Contact
Info
Blake Byers Ph.D GV Board Observer 000 0000
Carolyn Ng Ph.D Vertex Ventures HC Board Member 000 0000
Gladys Nunez Amgen Ventures Board Observer 000 0000
Jason Gardner Ph.D Self Board Member 000 0000
Karen Hong Ph.D Takeda Ventures Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »
Questions or concerns about this profile? Reach out to website-support@pitchbook.com